LGND

#1402
Ligand Pharmaceuticals Inc.
225.0900 USD
-3.12%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
225.0900
225.0900
Yıllık Aralık
175.8900
234.7600
Günlük Değişim
-3.12%
Aylık Değişim
+8.22%
6 Aylık Değişim
+20.29%
Yıllık Değişim
+20.29%
Önceki Kapanış
232.3400
Açılış
225.0900
Bid
Ask
Düşük
225.0900
High
225.0900
Hacim
49
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler Temettüler
Çeyreklik Yıllık
  • Market Capitalization 4.4886 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Total debt
Free cash flow
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
30.84
Price to sales ratio
14.31
Hisse başına temettü
2.5
Temettü getirisi %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Haberler